AGEN
HealthcareAgenus Inc.
$3.22
$-0.01 (-0.31%)
Jan 5, 2026
Price History (1Y)
Analysis
Agenus Inc. is a biotechnology company within the healthcare sector. It has a market capitalization of $109.51 million and generates revenue of approximately $106.83 million on an annualized basis. The company employs 316 people. Financially, Agenus Inc. has struggled with profitability, as evidenced by its operating margin of -16.1% and profit margin of -32.9%. Its gross margin is a low 0.1%. Additionally, the company has generated negative free cash flow of $148.29 million over the past four quarters. The balance sheet shows that Agenus Inc. has cash reserves of $3.46 million but also carries debt worth $46.15 million. Agenus Inc.'s valuation metrics are mixed. It has a forward price-to-earnings ratio of 1.65, which is lower than some peers. The company's revenue growth rate over the past year was 20.4%. However, Agenus Inc. does not pay dividends to its shareholders, as indicated by a payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Agenus Inc.
Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $109.51M
- P/E Ratio
- N/A
- 52-Week High
- $7.34
- 52-Week Low
- $1.38
- Avg Volume
- 526.39K
- Beta
- 1.58
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 316